Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine.

NCT00203307 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT00203307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00203307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine.
Lead sponsor
Thomas Jefferson University
Phase
Not applicable
Overall status
Terminated
Start date
May 31, 2004
Completion date
June 30, 2006
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine